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Abstract
Background: Increased activation of the renin-angiotensin system (RAS) may be important in
promoting coronary heart disease (CHD) and renal dysfunction, but limited data are available on
associations between angiotensin type 1 receptor (AGT1R) and angiotensinogen (AGT) genotypes in
type 2 diabetes.
Methods:  Study participants were diabetics from the Health Professionals Follow-Up Study
(HPFS) and the Nurses' Health Study (NHS). We analyzed single nucleotide polymorphisms (SNPs)
associated with cardiovascular pathophysiology (including AGT1R T573C, AGT1R A1166C, and AGT
M235T) and presence of renal dysfunction (eGFR<60 ml/min/1.73 m2) or history of CHD.
Results: The AGT1R 1166 C-allele was associated with eGFR<60 ml/min/1.73 m2 (multivariable OR
1.63 [1.01, 2.65]) in the HPFS men (n = 733) and in the combined dataset (n = 1566) (OR 1.42
[1.02, 1.98]). The AGT1R 1166 C-allele was also associated with CHD in men (OR 1.57 [1.10, 2.24]).
In NHS women (n = 833), AGT 235T-allele was associated with CHD (OR 1.72 [1.20, 2.47]).
Removal of hypertension from the fully adjusted models did not influence results, suggesting that
the associations may not be mediated by hypertension. There were significant interactions between
sex and AGT1R 1166 C-allele (p = 0.008) and AGT M235T (p = 0.03) in models for CHD. No
significant associations were seen between AGT1R T573 C-allele and renal dysfunction or CHD.
Conclusion: Polymorphisms in AGT1R and AGT genes are associated with renal dysfunction and
CHD in type 2 diabetes and further support the important role of the RAS in these complications.
Sex may modify associations between AGT1R 1166 C-allele and AGT 235T and CHD in type 2
diabetes.
Background
Increased activation of the renin-angiotensin system
(RAS) has been postulated to play a central role in the pro-
gression of chronic kidney disease (CKD) and coronary
heart disease (CHD). This theory is supported by rand-
omized clinical trials that have shown beneficial clinical
effects of the blockade of production of angiotensin-II
(AII) by angiotensin converting enzyme inhibitor (ACE-I)
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medications or antagonism of AII action through angi-
otensin receptor blockade (ARBs). For example, among
diabetics, the ARB losartan significantly slowed progres-
sion of CKD [1], whereas the ACE-I medication ramipril
significantly reduced CHD morbidity and mortality [2].
Although the D-allele of the ACE I/D polymorphism has
been associated with diabetic nephropathy in two large
meta-analyses of several thousand individuals [3,4], the
role of genetic polymorphisms in other components of
the RAS in CKD and CHD in people with type 2 diabetes
has been less well defined. Associations between these
SNPs and renal and cardiovascular diseases have been
reported in other sub-groups, however. For example, the
homozygous AGT (angiotensinogen gene) 235-T/T geno-
type has been associated with faster progression to ESRD
in patients with glomerulonephritis [5] and with suscepti-
bility to nephropathy in patients with type I diabetes mel-
litus [6], although not in two populations with type 2
diabetes [7,8].
Higher concentrations of plasma angiotensinogen are
associated with the AGT  235 T-allele [9] and may be
directly related to the number of Thr alleles present [10]
thereby supporting the theory that components in the
RAS are physiologically activiated and may promote
glomerulosclerosis and interstitial fibrosis via accumula-
tion of extracellular matrix [11]. Recent research has
revealed that another more clinically relevant AGT poly-
morphism may be a linked promoter substitution that
increases the rate of gene transcription; this G-6A poly-
morphism appears to be the one most strongly associated
with hypertension [12]. Genetic variation in AGT genes,
especially the AGT 235T and AGT (-6) G alleles have also
been reported to be associated with CHD [10,13,14].
Angiotensin II type 1 receptor (AT1R) polymorphisms
may influence intrarenal angiotensin II (AngII) activity.
Healthy Caucasians carrying the A1166 C-allele (AC or
CC) polymorphism showed lower basal GFR and basal
renal plasma flow and had increases in GFR following
treatment with the AT1R blocker losartan [15].
We therefore investigated associations of genetic poly-
morphisms in the AGT1R  and  AGT  genes including
AGT1R  T573C,  AGT1R  A1166C, and AGT  M235T and
presence of CKD and CHD in type 2 diabetes.
Methods
Participants
Health Professionals' Follow-Up Study
The Health Professionals' Follow-Up Study (HPFS) was
established in 1986 when 51,529 U.S. male health profes-
sionals, aged 40 to 75 at study initiation, returned a
mailed questionnaire providing information about diet,
lifestyle factors, and medical history [16]. Participants
were mailed follow-up questionnaires every two years to
update information. In 1993–1994, 18,159 participants
provided blood samples that were shipped on ice by over-
night delivery and stored at -130 degrees Celsius as previ-
ously described [17]. Diabetes mellitus (DM) was first
identified by self-report on a biennial questionnaire and
confirmed by a Diabetes Supplemental Questionnaire
(DSQ) in 2000; the validity of the DSQ in confirming DM
has been demonstrated in the HPFS cohort [18]. The
HPFS DM blood cohort consists of 1000 men with con-
firmed diabetes at baseline who provided a blood sample
in 1993–1994. Exclusion criteria for the current analyses
were as follows: a) age of onset of DM ≤ 25 years of age (to
attempt to restrict the study to type 2 DM) (n = 31), b)
subjects with a reported date of DM diagnosis after the
date of blood draw (n = 224), c) participants who
reported on the DSQ that they were on dialysis (n = 9) or
had a kidney transplant (n = 1), d) serum creatinine > 5.0
mg/dl (n = 1), and e) serum creatinine ≤ 0.5 mg/dl (felt to
be physiologically implausible) (n = 1). After these exclu-
sions, 733 men were available for analysis.
Nurses' Health Study
The NHS was initiated in 1976 with the enrollment of
121,700 U.S. nurses aged 30–55 years. This cohort is fol-
lowed through questionnaires related to lifestyle factors
and health outcomes that are mailed biennially. In 1989,
32,826 participants provided blood samples that were
shipped on ice by overnight delivery and stored at -130
degrees Celsius as previously described [19]. Of these
study participants who provided blood samples in 1989–
1990, 1,198 who had a confirmed diagnosis of type 2 dia-
betes were chosen as a NHS diabetes blood sub-cohort.
Exclusion criteria for the current analyses were: a) age of
onset of DM ≤ 25 years of age (to attempt to restrict the
study to type 2 DM) (n = 39), b) subjects with a reported
date of DM diagnosis after the date of blood draw (n =
304), and c) serum creatinine ≤ 0.5 mg/dl (likely to be a
laboratory error and physiologically implausible) (n =
22). No NHS participants reported on the DSQ being on
dialysis or having had a kidney transplant. After these
exclusions, 833 women had data available for analysis.
This study was approved by the Partners' Healthcare
Brigham and Women's Hospital Human Research Com-
mittee Institutional Review Board.
Assessment of covariates
Race was initially reported on the 1986 questionnaire for
HPFS and in 1992 for NHS. Other clinical and lifestyle
variables were derived from data from the questionnaire
closest to the blood collection, i.e. the 1994 questionnaire
for HPFS and the 1990 questionnaire for NHS. Body mass
index (BMI) was calculated by weight (kg/m2). A weeklyBMC Nephrology 2009, 10:9 http://www.biomedcentral.com/1471-2369/10/9
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metabolic-equivalent (MET) score was calculated from
the physical activity questions. Self-reported hypertension
[18] and smoking status [20] have also been previously
validated in these cohorts.
Laboratory Methods
Single-nucleotide polymorphisms (SNP) analyses
DNA was extracted from the buffy coat fraction of centri-
fuged blood using the QIAmp Blood Kit (Qiagen, Chats-
worth, CA). All SNPs were genotyped using Taqman SNP
allelic discrimination by means of an ABI 7900 HT
(Applied Biosystems, Foster City, CA). Undetermined
SNP results, which comprised of <10% of data for any
individual SNP, were treated as missing values. The candi-
date SNPs investigated here were AGT1R T573C (rs5182),
AGT1R A1166C (rs5186), AGT M235T (rs699), and AGT
A(-6)G (rs5051). A concordance rate of 100% was seen in
108 blinded quality control samples for all SNPs assayed.
Estimation of kidney function
Plasma creatinine was measured by a modified kinetic
Jaffe reaction with a coefficient of variation of 22% for
HPFS and 10% for NHS. Renal function was estimated by
the simplified MDRD equation where estimated glomeru-
lar filtration rate (eGFR) (ml/min/1.73 m2) = 186 × [PCr
(mg/dl)]-1.154 × [Age]-0.203 × [0.472 if female] × [1.21 if
black] [21] and the Cockcroft-Gault equation where esti-
mated creatinine clearance (CrCl) = ([140-age (years) ×
weight (kg) × (0.8 if female)]/(Pcr × 72)) [22]. Moderate
renal dysfunction was considered to be eGFR < 60 ml/
min/1.73 m2 or CrCl < 60 ml/min. Because results using
CrCl < 60 ml/min were very similar to those using eGFR <
60 ml/min/1.73 m2, we present only the eGFR analyses.
Ascertainment of Coronary Heart Disease
Coronary heart disease was defined as history of con-
firmed myocardial infarction, or self-reported coronary
revascularization or angina. These self-reported outcomes
have been previously validated by medical chart review
[23].
Statistical Analyses
In our primary analyses, we tested for associations of SNPs
and outcomes using a dominant model where the pres-
ence of the disease allele (listed second in the SNP name
as per convention) was considered the exposure of inter-
est. We also examined recessive models, where the
homozygous disease genotype was compared to all oth-
ers, as well as additive genetic models, where the impact
of each additional presumed disease allele was assessed.
Unconditional logistic regression was used to calculate
odds ratios for GFR < 60 ml/min/1.73 m2 or CrCl < 60 ml/
min or presence of CHD. Multivariable models were
adjusted for age (continuous, years), hypertension (yes/
no), BMI (continuous), cigarette smoking status (never,
past, current), physical activity (quartiles, METS/week),
duration of type 2 diabetes (quartiles, years), and meas-
ured HgbA1c (quartiles). In the analyses of the combined
cohorts, sex was included as a covariate in addition to all
those variables included in fully-adjusted models strati-
fied by sex. Coronary heart disease (yes/no) was also
included as a covariate in models where eGFR < 60 ml/
min/1.73 m2 or CrCl < 60 ml/min were the outcome of
interest. Estimated GFR < 60 ml/min/1.73 m2  was
included as a covariate for CHD analyses. All analyses
were performed with SAS software, version 9.1 (SAS Insti-
tute, Inc., Cary, North Carolina).
Results
Demographic and clinical information for HPFS and NHS
participants with Type 2 diabetes are shown in Table 1.
Participants were predominantly Caucasian, the majority
was overweight or obese, and the mean time since diagno-
sis of type 2 diabetes was 10 to 11 years. Most participants
had well-preserved renal function: only 90 HPFS men and
80 NHS women had eGFR < 60 ml/min/1.73 m2. Approx-
imately 25% of participants had prevalent CHD. Only 38
(5%) participants in HPFS and 42 (5%) participants in
NHS had both eGFR<60 ml/min/1.73 m2 and CHD.
AGT A(-6)G is in complete linkage disequilibrium with
M235T and results were almost identical between the two
SNPs; therefore, we present only the results for AGT SNPs
from the M235T analyses. Prevalence of the disease-asso-
ciated allele ranged from 47% for AGT1R 1166 C-allele to
68% for the AGT1R 573 C-allele. Prevalence of homozy-
gosity for the disease-associated allele ranged from 9% for
AGT1R 1166 C-allele to 20% for the AGT1R 573 C-allele.
The SNPs were in Hardy-Weinberg equilibrium (all p-val-
ues for chi-square test ≥ 0.60).
For all SNPs, the magnitude of the fully adjusted odds
ratios for the dominant models showed little difference
when compared to the age-adjusted only models (Table
2). For the outcome of eGFR < 60 ml/min/1.73 m2, a sig-
nificantly elevated odds ratio was seen in the fully-
adjusted model for the AGT1R 1166 C-allele in the HPFS
men only (Table 2). Adjusted dominant models that did
not include prevalent hypertension for the outcome of
eGFR < 60 ml/min/1.73 m2 were not different from the
fully adjusted models. When the two cohorts were com-
bined, the AGT1R 1166 C-allele remained significantly
associated with eGFR < 60 ml/min/1.73 m2 (adjusted OR
1.42 [1.02, 1.98]) (Figure 1); no significant associations
were seen in recessive or additive models in the combined
dataset. Results using CrCl<60 ml/min as the outcome of
interest were similar to those using eGFR < 60 ml/min/
1.73 m2 (results not shown).BMC Nephrology 2009, 10:9 http://www.biomedcentral.com/1471-2369/10/9
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For the outcome of CHD, the AGT1R 1166 C-allele in
dominant model was associated with a significantly
higher odds ratio in men while the AGT SNP M235T was
associated with a significantly higher odds ratio in women
(Table 2). Recessive inheritance modeling was borderline
significant only for the AGT M235T (adjusted OR 1.52
[0.98 to 2.35]) for the presence of CHD in women. No
recessive models were significant for men, and all additive
models were null for both groups. Multivariable models
that did not include prevalent hypertension yielded the
same results as the fully adjusted models. Excluding eGFR
< 60 ml/min/1.73 m2 as a covariate in the models for
CHD also did not influence the associations seen.
The AGT 235 T-allele had a borderline association with
history of CHD (OR 1.24 [0.96, 1.61] in the pooled data
(Figure 1). The fully adjusted odds ratios for the com-
bined data were not notably different from the age-
adjusted only odds ratios (all differences resulted in <
10% change in OR). Results for CHD outcome did vary by
sex; we observed significant interaction term p-values for
the AGT1R 1166 C-allele (p = 0.008) and AGT 235 T-allele
(p = 0.03) in relation to CHD (Table 2). In the combined
data set, no significant associations were observed in
recessive or additive models for CHD.
Because different allelic frequencies may be seen in differ-
ent ethnic populations, we also analyzed these data with
the few African-Americans excluded. Exclusion of these
participants did not meaningfully change any of the
results in the analyses stratified by sex or in the combined
cohort. For example, the odds ratio for AGT1R A1166 C-
allele was 1.70 [1.04, 2.78] for eGFR < 60 ml/min/1.73 m2
and 1.56 [1.09, 2.21]for CHD when African-Americans
were excluded from the HPFS analyses. Similarly in the
combined cohort, the odds ratio for AGT1R  A1166 C-
allele and eGFR < 60 ml/min/1.73 m2 was 1.42 [1.02 to
1.98].
Table 1: Demographic and clinical characteristics of type 2 diabetics in the Health Professionals Follow-Up Study (HPFS) and Nurses' 
Health Study (NHS)
HPFS in 1994
(n = 733)
NHS in 1990
(n = 833)
Age (years) 65.5 ± 7.9 (47–80) 59.5 ± 6.3 (43–70)
African-American 11 (1.5) 12 (1.4)
Hypertension 399 (45.6) 568 (68.2)
Weight (kg) 88.1 ± 16.2 (56.8–210.9) 80.4 ± 18.1 (38.6–154.5)
Body Mass Index (BMI) (kg/m2) 27.8 ± 4.4 (18.3–56.5) 29.9 ± 6.2 (15.1–54.9)
BMI categories (kg/m2)
<22 33 (4.5) 78 (9.3)
22–24.9 160 (21.8) 102 (12.2)
25–27.9 229 (31.2) 155 (18.6)
28–29.9 131 (17.9) 110 (13.2)
≥ 30 180 (24.6) 384 (46.1)
Activity (METs/week) 29.6 ± 33.0 (0–228.8) 15.3 ± 20.3 (0.2–190.7)
Cigarette smoking
Current 43 (5.8) 113 (13.6)
Past 392 (53.5) 341 (40.9)
Never 261 (35.7) 377 (45.3)
Missing 37 (5.1) 2 (0.2)
Time since diagnosis of Type 2 diabetes (years) 11.2 ± 9.1 (0.1–41.1) 10.3 ± 8.0 (0.1–41.1)
Measured HbA1c (%) 7.5 ± 1.6 (4.8–15.6) 7.2 ± 1.8 (4.4–15.4)
Baseline coronary heart disease (MI, revascularization, or angina) 194 (26.5) 216 (25.9)
ACE-inhibitor medication use 60 (8.2) 81 (9.7)
Statin medication use 48 (6.6) Not available
Measured plasma creatinine (mg/dl) 1.1 ± 0.2 (0.6–2.9) 0.8 ± 0.2 (0.5–2.4)
Creatinine clearance (ml/min) 91 ± 30 (22–241) 100 ± 33 (17–244)
eGFR (ml/min/1.73 m2) 79 ± 18 (23–142) 83 ± 19 (22–139)
Results expressed as mean ± SD (range 0 to 100%) or no. (%)
ACE = Angiotensin-converting enzyme
eGFR= Estimated glomerular filtration rateBMC Nephrology 2009, 10:9 http://www.biomedcentral.com/1471-2369/10/9
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Discussion
The AGT1R 1166 C-allele was directly and significantly
associated with renal dysfunction in the combined data-
set. This SNP was also associated with higher odds ratio
for prevalent CHD in men with type 2 diabetes whereas
the AGT 235 T-allele was significantly associated with
increased odds ratio for CHD in women with type 2 dia-
betes. In contrast to the majority of previous publications
of  AGT1R  and  AGT  polymorphisms, this study only
included adults with type 2 diabetes, which is a popula-
tion especially at high risk for kidney dysfunction and
CHD.
We also found that sex might modify the association
between SNPs and presence of CHD, and recommend
that future investigations consider stratifying analyses by
sex. A biological basis for these observed sex differences
may be indirectly supported by previous studies of the
RAS. For example, a population study of several hundred
Bavarians revealed higher renin and prorenin levels in
men compared with women; the authors also noted the
lowest renin and prorenin levels in women taking hor-
mone replacement therapy and hypothesized that sex hor-
mones may regulate expression of the renin gene [24].
Healthy men also exhibit greater decreases in plasma
renin and angiotensin-II levels than healthy women when
given angiotensin-receptor blocker medications [25].
Another investigation of 93 healthy young men and
women also reported higher levels of angiotensin-(1–7)
peptides in men compared to women, but did not detect
significant differences in levels of A-I, A-II, or angiotensin-
(1–7) between the sexes when stratified by AGT1R 1166
C-allele or AGT M235T genotypes [26]; however, the
study had low power because many subgroups analyzed
had less than 10 people.
We examined dominant, recessive, and additive genetic
models for each of these four SNPs and eGFR< 60 ml/
min/1.73 m2 and CHD and did not detect significant asso-
ciations with recessive models or additive models. Previ-
ous analyses of the AGT  M235T SNP and CHD have
reported an association with the homozygous T/T variant
[10,13,14], but these relatively small studies may not have
had enough power to effectively identify recessive genetic
effects.
Our findings that the AGT1R 1166 C-allele was associated
with renal dysfunction in men and women with type 2
diabetes is consistent with a smaller French study of 235
type 2 diabetics where the authors reported that the CC
genotype was significantly associated with nephropathy
(defined as presence of microalbuminuria) especially in
men[27]. Although previous case-control studies demon-
strated an increased frequency of the AGT1R 1166 C-allele
in ESRD patients with [28] and without type 2 diabetes
[29] compared to healthy controls, our study appears to
be one of the few to examine an earlier stage of moderate
kidney dysfunction. In contrast, other studies have not
found association between A1166 C-allele and nephropa-
thy in type 2 diabetes [30,31].
Consistent with our findings, however, a study of 132 Jap-
anese adults with type 2 diabetes [32], a Hong Kong study
of 168 type 2 diabetics [33], a study from Germany of 301
type 2 diabetics [34], and a meta-analysis of several thou-
sand people [35] reported no association between neph-
ropathy and the AGT M235T polymorphism. In contrast,
a recent investigation of 421 Asian Indian type 2 diabetics
did find an association between the AGT 235 T-allele and
renal insufficiency (defined as plasma creatinine ≥ 3 mg/
dl and/or urinary albumin excretion rate > 200 mcg/min)
(OR 2.68, 95%CI 2.01 to 3.57) [36].
Direct comparisons of conflicting reports in the literature,
however, may be difficult and discrepancies could be due
to many factors such different prevalence in genetic poly-
morphisms in different ethnic populations as well as var-
ying definitions of nephropathy (impaired eGFR or CrCl
in our study vs. microalbuminuria in other studies) and
varying sample sizes. For example, the frequencies of the
AGT 235 T-allele and the AGT (-6) G-allele appear to be
much higher in Japanese compared with Caucasian popu-
lations [12].
Interestingly, the associations observed between these
candidate RAS SNPs and renal dysfunction were not
meaningfully changed after multivariable adjustment. In
particular, excluding hypertension as a covariate from the
Adjusted odds ratios for dominant model RAS SNPs and  eGFR<60 ml/min/1.73 m2 and CHD in combined cohort of  HPFS (men) and NHS (women) with type 2 diabetes Figure 1
Adjusted odds ratios for dominant model RAS SNPs 
and eGFR<60 ml/min/1.73 m2 and CHD in combined 
cohort of HPFS (men) and NHS (women) with type 2 
diabetes. Error bars represent 95% confidence intervals.
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model did not change results and support the concept that
association between RAS SNPs (and presumed upregula-
tion of the RAS) and renal and CHD outcomes may be
mediated by other influences in besides hypertension,
which likely include cellular hyperplasia, stimulation of
hormonal pathways and direct pro-fibrotic effects on the
kidneys and vasculature [11]. Other investigators have
also reported that hypertension may not mediate associa-
tions between these SNPs and CHD [13] or progressive
CKD [37]. Also notable is the lack of influence of includ-
ing eGFR < 60 ml/min/1.73 m2 as a covariate in models
where CHD was the dependent variable, which may sug-
gest that renal dysfunction has a weaker association with
CHD in type 2 diabetes (who have often have multiple
overlapping vascular risk factors) than in non-diabetic
populations.
Some important limitations of this investigation need to
be acknowledged. Data on albuminuria, another measure
of kidney dysfunction in addition to eGFR or CrCl were
not available in the men and the majority of the women.
Kidney function was not directly measured but estimated
by a single measurement of plasma creatinine in each par-
ticipant. The participants were mostly Caucasians and the
findings may not be generalizable to other ethnic groups.
There are no measurements of plasma angiotensiongen
levels or other markers of RAS activation available to cor-
relate directly with the genetic polymorphisms investi-
gated here. The relatively small sample sizes and few
numbers of participants meeting criteria for kidney dys-
function has resulted in wide confidence intervals for
many of the estimates for eGFR < 60 ml/min/1.73 m2.
Also, as the DNA was collected several years after the ini-
tiation of the cohort study, there is a possibility that par-
ticipants who died prior to the blood collection may have
had the candidate SNPs; this situation would be expected
to bias results towards the null, however, whereas we did
observe a number of significant associations.
Strengths of the current study include the examination of
genetic polymorphisms in the RAS that have received less
attention than the ACE-I/D genotype, which provide
Table 2: Logistic regression dominant models for association of RAS SNPs with presence of moderate renal dysfunction (GFR < 60 ml/
min/1.73 m2) or CHD
HPFS (n = 733) NHS (n = 833)
Number of 
cases/Total 
number with 
allele (%)
Age-adjusted 
OR
[95% CI]
Multivariable 
OR*
[95% CI]
Number of 
cases/Total 
number with 
allele (%)
Age-adjusted 
OR
[95% CI]
Multivariable 
OR*
[95% CI]
p-value for 
sex *SNP 
interaction
For GFR <60 
ml/min/1.73 m2
AGT1R 
T573C 
(C-allele)
54/480
(11%)
0.68
[0.42, 1.09]
0.60
[0.36, 1.00]
68/569 (12%) 1.11
[0.68, 1.82]
0.96
[0.57, 1.61]
0.21
AGT1R 
A1166C 
(C-allele)
51/346
(15%)
1.59
[0.99, 2.49]
1.63
[1.01, 2.65]
50/402 (12%) 1.18
[0.76, 1.83]
1.28
[0.80, 2.04]
0.54
AGT 
M235T 
(Thr)
57/469
(12%)
0.98
[0.61, 1.56]
0.91
[0.55, 1.49]
68/527 (13%) 1.62
[0.99, 2.69]
1.46
[0.85, 2.50]
0.25
For prevalent 
CHD
AGT1R 
T573C 
(C-allele)
133/480 (28%) 1.26
[0.85, 1.85]
1.36
[0.91, 2.02]
148/569 (26%) 1.07
[0.75, 1.53]
1.02
[0.69, 1.49]
0.45
AGT1R 
A1166C 
(C-allele)
105/346 (30%) 1.62
[1.14, 2.29]
1.57
[1.10, 2.24]
99/402 (25%) 0.84
[0.61, 1.16]
0.85
[0.61, 1.20]
0.008
AGT 
M235T 
(Thr)
120/469 (26%) 0.95
[0.66, 1.35]
0.92
[0.64, 1.33]
154/527 (29%) 1.72
[1.20, 2.47]
1.66
[1.13, 2.43]
0.03
*Multivariable models are adjusted for age (continuous, years), hypertension (yes/no), BMI (continuous), cigarette smoking status (never, past, 
current), physical activity (quartiles, mets/week), time since Type 2 diabetes diagnosis (quartiles, years), and measured HbA1c (quartiles). 
Multivariable models for renal dysfunction are adjusted for presence of coronary heart disease (yes/no) and multivariable models for CHD are also 
adjusted for eGFR<60 ml/min/1.73 m2. ACE-inhibitor use did not change point estimates when included in the model and was removed.
GFR < 60 ml/min/1.73 m2 by the 4-variable MDRD equation was considered renal dysfunction. Coronary heart disease was defined as history of 
confirmed myocardial infarction, or self-reported coronary revascularization or angina.BMC Nephrology 2009, 10:9 http://www.biomedcentral.com/1471-2369/10/9
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novel information concerning genetics and kidney and
cardiac disease in adults with type 2 diabetes. Further-
more, by examining the SNPs separately in a cohort of
men and one of women as well as in a combined dataset,
these analyses revealed that sex may modify the associa-
tion between RAS gene polymorphisms and coronary
heart disease in type 2 diabetes.
Conclusion
In conclusion, among type 2 diabetics, the AGT1R 1166
C-allele is directly associated with kidney dysfunction in
men and women but with CHD only in men. The AGT
235 T-allele is associated with CHD in women. Previous
evidence suggests that these polymorphisms are associ-
ated with up-regulation of the RAS, and therefore, these
data further support the central role of RAS activation in
CKD and CHD.
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